A randomized non-comparative phase II study of maintenance therapy with FOLFIRI alone or in combination with Tedopi vaccine after induction therapy with FOLFIRINOX in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (TEDOPAM D17-01 PRODIGE 63 STUDY)
ANNÉE
2021
AUTEURS
HiImi M, Hautefeuille V, Lambert A, Garcia-Larnicol ML, Vernerey D, Neuzillet C
CONGRÈS/REVUE
ESMO
LIEN PUBLICATIONS ASSOCIÉES